Literature DB >> 9010261

Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease.

G Wei1, S Yano, T Kuroiwa, K Hiromura, A Maezawa.   

Abstract

A low serum complement level is commonly found in patients with rheumatic diseases. We evaluated 170 patients with such diseases to determine their serum levels of CH50, C3 and C4 protein. Persistent hypocomplementaemia was found in 19 of those patients, particularly in those with systemic lupus erythematosus (SLE). Cold-dependent activation of complement (CDAC) was demonstrated in nine of the 19 (47.4%), and six of the nine patients demonstrated infection with HCV (66.7%). The nine patients that exhibited CDAC had nearly normal haemolytic complement activity when the sera were separated either at 37 degrees C or in EDTA-treated plasma. Conversely, it markedly decreased, even to the point of being immeasurable, when the sera were separated at 4-21 degrees C. No significant deficiency in C3 and C4 protein levels was found in these patients. Clinical parameters other than levels of anti-HCV antibody, transaminase, and RF were not influenced by CDAC. In an attempt to isolate the causal factor for CDAC, we isolated IgG fractions from the CDAC patients by using a protein G column, in which case precipitates were collected from the eluates. The precipitates were mixed with normal serum and incubated at 4-21 degrees C for 18 h. A decrease in the level of CH50 in normal serum was observed, which predominated (P < 0.001) when precipitates from HCV-infected patients were used. This indicated CDAC was possibly interrelated to the precipitates of such patients. This precipitate was proved to contain IgM besides IgG. It is therefore possible that an HCV-related IgG complex or an IgG-IgM RF complex may be formed at low temperature and be involved in activating the complement system in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010261      PMCID: PMC1904537          DOI: 10.1046/j.1365-2249.1997.d01-882.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  5 in total

1.  Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.

Authors:  C Dumestre-Perard; D Ponard; C Drouet; V Leroy; J-P Zarski; N Dutertre; M G Colomb
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

2.  Pre-pregnancy serum complement C3 level is a predictor of preterm birth for pregnancies with systemic lupus erythematosus.

Authors:  Yuri Hiramatsu; Kentaro Isoda; Takuya Kotani; Eri Nakamura; Yumiko Wada; Youhei Fujiki; Shigeki Makino; Daisuke Fujita; Tohru Takeuchi
Journal:  Arthritis Res Ther       Date:  2021-05-12       Impact factor: 5.156

3.  Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia.

Authors:  Sabino Russi; Domenico Sansonno; Maria Addolorata Mariggiò; Angela Vinella; Fabio Pavone; Gianfranco Lauletta; Silvia Sansonno; Franco Dammacco
Journal:  Arthritis Res Ther       Date:  2014-03-18       Impact factor: 5.156

Review 4.  Rheumatoid factor, complement, and mixed cryoglobulinemia.

Authors:  Peter D Gorevic
Journal:  Clin Dev Immunol       Date:  2012-08-26

5.  Autoimmune hemolytic anemia occurred prior to evident nephropathy in a patient with chronic hepatitis C virus infection: case report.

Authors:  Isao Ohsawa; Yuki Uehara; Sumiko Hashimoto; Morito Endo; Takayuki Fujita; Hiroyuki Ohi
Journal:  BMC Nephrol       Date:  2003-08-29       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.